Policy & Regulation
La Jolla Institute for Immunology and Kyowa Kirin sign new collaboration contract
19 January 2022 -

US-based La Jolla Institute for Immunology and Japan-based pharmaceutical company Kyowa Kirin Inc, a wholly-owned subsidiary of Kyowa Kirin Co. Ltd (Kyowa Kirin, TSE: 4151), announced on Tuesday that they have signed a new collaboration agreement.

The contract continues a successful research alliance, first signed over three decades ago between both parties. The new research collaboration raises annual funding and offers for more engagement of La Jolla Institute for Immunology faculty and Kyowa Kirin researchers. The contract will be valid until the end of 2024. The continuing collaboration intends to utilise Kyowa Kirin's drug discovery, antibody engineering, and development capabilities and La Jolla Institute for Immunology's pioneering expertise in fundamental immunological research to expedite the translation of research discoveries into new therapies intended to improve human health.

According to the terms of the contract, La Jolla Institute is to receive a combination of discretionary research funding, funds reserved for projects within Kyowa Kirin's therapeutic areas of interest, with an emphasis on human translational potential, faculty recruitment and, for the first time, projects spearheaded by La Jolla Institute for Immunology postdoctoral fellows and graduate students. Kyowa Kirin is to receive first rights to negotiate for a license to La Jolla Institute discoveries resulting from research projects funded under the contract.